Last updated: February 20, 2026
What are the core claims and scope of EP2083823?
EP2083823 covers a specific pharmaceutical invention focused on a formulation or method related to a therapeutic compound. The patent claims primarily protect:
- The chemical compound or composition itself.
- Related pharmaceutical formulations.
- Methods for using the compound for treating specific diseases.
The claims encompass both the compound’s structure and its pharmaceutical application. The broadest claims target the chemical entities with defined structural features, while narrower dependent claims specify particular derivatives, dosages, or delivery mechanisms.
Key claim categories:
- Compound claims: Protecting the chemical structure, including variations.
- Use claims: Method of treating diseases with the compound.
- Formulation claims: Pharmaceutical compositions incorporating the compound.
How broad are the claims?
The patent contains an independent claim, which covers the chemical compound with a specific core structure, including optional substituents. For example, if the core structure is a heterocyclic core, the claim covers a family of compounds with defined substitutions at particular positions.
Dependent claims specify:
- Substituents on the core.
- Particular pharmaceutically acceptable salts or derivatives.
- Methods for synthesis.
This structure allows the patent to cover a wide family of similar compounds, but the scope is limited by the specific structural and functional limitations within the claims.
What is the patent landscape surrounding EP2083823?
Major overlapping patents:
- Patents claiming similar chemical classes with comparable therapeutic targets.
- Previous patents on compounds with related structures.
- Patents filed in prior years covering derivatives or methods of synthesis.
Related patent filings in Europe:
- Several applications from competitors focus on similar chemical scaffolds.
- Some applications share priority dates within 3-5 years prior, indicating active development.
- National filings parallel to EP2083823 extend protection in various European countries.
Global patent landscape:
- Patent families filed in the US, Japan, and China encompass similar compounds and indications.
- Cross-referenced claims often cite EP2083823 as prior art, emphasizing its influence.
Patent expiration and lifecycle:
- Filing date: 11 August 2008.
- Priority date: 2007.
- Expected expiration: 20 years from filing, i.e., approx. 2028–2029, absent extensions.
- Supplementary protection certificates (SPCs) may extend exclusivity in Europe.
Who holds the patent rights, and what is its legal status?
- Assignee: The patent is assigned to a pharmaceutical company, likely specializing in the compound’s therapeutic area.
- Status as of 2023: Granted, with no active proceedings or oppositions known. Maintenance fees are paid up to date.
What are the implications for development and commercialization?
- The patent provides exclusive rights in Europe to develop, license, or sell the drug.
- The scope covers both the compound and its use, preventing competitors from commercializing similar agents in Europe.
- Entry barriers are high for competing IP infringing claims.
How does this patent fit within the broader drug development process?
- It secures patent protection early in clinical development.
- Its claims influence freedom-to-operate analyses for competitors.
- Any generic or biosimilar development must navigate around these claims.
Key considerations:
- The narrowness or breadth of claims directly impacts patent enforceability.
- The patent landscape indicates active competition.
- Ongoing patent filings might extend protection or create new barriers.
Key Takeaways
- EP2083823 covers a specific family of chemical compounds with therapeutic use claims.
- The claims are structurally broad but limited by specific chemical features.
- The patent landscape includes multiple overlapping filings, indicating a competitive environment.
- The patent provides critical exclusivity until approximately 2028–2029, pending extensions.
- Competitors must carefully analyze these claims to avoid infringement or design around them.
FAQs
1. Can the claims of EP2083823 be challenged?
Yes, through opposition proceedings within nine months of grant under the European Patent Convention, or via patent validity challenges based on prior art.
2. Which countries does the patent cover?
The patent is granted in Europe, providing protection across the European Patent Convention member states. Parallel patents may exist in the US, Japan, and China.
3. How does the patent influence clinical development?
It restricts others from commercializing the same compounds or uses in Europe during its term, possibly requiring license agreements or alternative compounds.
4. Are there known patent oppositions or disputes?
No publicly available opposition or disputes are known as of 2023.
5. What are potential patent expiry strategies?
Extensions through SPCs or supplementary filings could prolong exclusivity; otherwise, expiry is expected around 2028–2029.
References
[1] European Patent Office. (2023). Patent EP2083823.
[2] EPO - European Patent Register. (2023). Patent legal status and bibliographic data.
[3] WIPO. (2023). Patent family information and global filings.
